What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.

In October 2013, we created a new, full-time position to lead our CR efforts. Juergen Brokatzky-Geiger, formerly Global Head of Human Resources and a member of the Executive Committee, took on this role effective in February 2014.

Novartis is working to tackle the problem of counterfeit drugs, which are a threat to patient health.

The word “biopsy” typically conjures images of large needles. Lab technicians—and scientists working to discover new medicines—need enough tissue from a patient to prepare and evaluate a sample.